Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians
- PMID: 28762375
- PMCID: PMC5667647
- DOI: 10.1038/ajg.2017.215
Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians
Abstract
Objectives: Idiosyncratic drug induced liver injury (DILI) is a rare but potentially serious liver disorder and a major cause of significant liver injury. Limited data exist on racial differences in DILI incidence, presentation, and course.
Methods: We compared the causative agents, clinical features, and outcomes of DILI among self-described African-Americans and non-Hispanic whites (Caucasians) enrolled in the DILIN Prospective Study. Individuals with definite, highly likely, or probable DILI enrolled between September 2004 and February 2016 were included in this analysis.
Results: 144 African-Americans and 841 Caucasian patients met the eligibility criteria. Causal medications varied by race: trimethoprim/sulfamethoxazole being the most common cause among African-Americans (7.6 vs. 3.6%) followed by methyldopa (4 vs. <1%), phenytoin (5 vs. <1%), isoniazid (4 vs. 4%), and amoxicillin/clavulanate (4.1 vs. 13.4%). The severity of illness, however, tended to be greater in African-Americans than Caucasians as determined by peak mean bilirubin (14.3 vs. 12.8 mg/dl), INR (1.9 vs. 1.6), and DILIN severity score (3.0 vs. 2.6). The frequency of severe cutaneous reactions was significantly higher in African-Americans (2.1 vs. 0.36% in Caucasians, P=0.048). African-Americans also had higher rates of hospitalization (76.7 vs. 57.6%, P<0.001), liver transplantation or liver related death by 6 months (10.2 vs. 5.8%, P=0.02 after controlling for selected covariates), and chronic DILI (24 vs. 16%, P=0.06).
Conclusions: The most common DILI causative agents differ between African-Americans and Caucasians. African-Americans are more likely to have severe cutaneous reactions and more severe liver injury leading to worse outcomes, including death and liver transplant.
Conflict of interest statement
References
-
- Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug induced liver injury in general population. Gastroenterology. 2013;144:1419–1425. - PubMed
-
- Chalasani N, Bonkovsky HL, Fontana RJ, Vuppalanchi R, Hayashi PH, Navarro V, Reddy KR, Lee WM, Davern T, Barnhart H, Atolz A, Kleiner DE, Talwalkar J, Serrano J, Gu J, Watkins PB, Hoofnagle J. Drug-induced liver injury in the United States: A report of 899 events prospectively assessed. Gastroenterology. 2015;148:1340–1352.
MeSH terms
Grants and funding
- U01 DK065211/DK/NIDDK NIH HHS/United States
- UL1 RR025761/RR/NCRR NIH HHS/United States
- U01 DK083027/DK/NIDDK NIH HHS/United States
- U01 DK083020/DK/NIDDK NIH HHS/United States
- U01 DK065238/DK/NIDDK NIH HHS/United States
- U01 DK065193/DK/NIDDK NIH HHS/United States
- U01 DK065176/DK/NIDDK NIH HHS/United States
- U01 DK083023/DK/NIDDK NIH HHS/United States
- UL1 RR024982/RR/NCRR NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- U01 DK065201/DK/NIDDK NIH HHS/United States
- U01 DK100928/DK/NIDDK NIH HHS/United States
- UL1 TR002240/TR/NCATS NIH HHS/United States
- UL1 TR000083/TR/NCATS NIH HHS/United States
- UL1 RR024986/RR/NCRR NIH HHS/United States
- U01 DK065184/DK/NIDDK NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- U01 DK082992/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
